Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody 

Slides:



Advertisements
Similar presentations
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Advertisements

Assessment and Diagnosis of Dementia Dr Alison Haddow.
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Sleep disruption changes across the disease trajectory: Pilot findings from the healthy patterns sleep study Nancy A. Hodgson, Albert J. Safi Alzheimer's.
DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE  Kathryn A. Wyman-Chick, Phillip.
Aka STEEL VALLEY SENIORS SURVEY (SVSS)
2017 Alzheimer's disease facts and figures
Volume 1, Issue 1, Pages (June 2015)
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  Wesley.
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease  Azadeh Karami, Helga Eyjolfsdottir, Swetha.
Chapter 7 Health Assessment
From ESH 2016 | POS 3C: Chiara Lorenzi, MD
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Copyright © 2000 American Medical Association. All rights reserved.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
2016 Alzheimer's disease facts and figures
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Christine Bredfeldt, Kristen Rice, Lisa Alecxih 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging  Vincenzo Solfrizzi, Emanuele Scafato, Vincenza Frisardi,
Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis  Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,
Application of Resource Utilization in Dementia (RUD) instrument in a global setting  Anders Wimo, Anders Gustavsson, Linus Jönsson, Bengt Winblad, Ming-Ann.
2014 Alzheimer's disease facts and figures
Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang 
Is Early Placement Better in Alzheimer's Disease?
Early Dementia Distinguishing AD From MCI
Mark V. Johnston, PhD, Daniel Graves, PhD, Maureen Greene, MS 
2017 Alzheimer's disease facts and figures
چون آن مرغی که درهر برگ گل نقش خزان بیند
2017 Alzheimer's disease facts and figures
Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis  Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,
Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias Dement.
Martin R. Farlow, MD  Mayo Clinic Proceedings 
Ali F. AbuRahma, MD  Journal of Vascular Surgery 
Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study  Katherine Donegan,
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
A New Era of Renal Denervation Trials for Patients With Hypertension?
Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola 
This Month in AJKD American Journal of Kidney Diseases
Application of Resource Utilization in Dementia (RUD) instrument in a global setting  Anders Wimo, Anders Gustavsson, Linus Jönsson, Bengt Winblad, Ming-Ann.
Reducing antibiotic use in influenza: challenges and rewards
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Checkpoint Inhibitors in First-Line Advanced NSCLC
Arnold S. Relman, MD, American Journal of Kidney Diseases
Prospective Clinical Trial Registration
Table of contents The Journal for Nurse Practitioners
LIFESPAN OF ONE FOCUSED ULTRASOUND MEDIATED BLOOD-BRAIN BARRIER TREATMENT IN A MOUSE MODEL OF ALZHEIMER'S DISEASE  Charissa Poon, Kullervo Hynynen  Alzheimer's.
2014 Alzheimer's disease facts and figures
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
Introduction: Evolution of military and veterans brain health research
A biomarker signal: Context-dependent hippocampal fMRI connectivity analysis of clinical trial measures in Alzheimer's disease  Donald McLaren, Reisa.
Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An,
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS  Betty M. Tijms, Mara ten Kate, Sander C.J.
2018 Alzheimer's disease facts and figures
Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years  Kevin A. Matthews,
Receiver operating characteristics curves showing discrimination between patients with dementia of the Alzheimer type (at time of diagnosis) and non-demented.
Increased risk for dementia both before and after stroke: A population-based study in women followed over 44 years  Xinxin Guo, Svante Östling, Silke.
Harry E. Scher, DNP, APRN, Michelle L. Drew, DNP, FNP, Damon B
 Conceptual diagram of acetylcholine system and disease and drug effects.  Conceptual diagram of acetylcholine system and disease and drug effects. Relative.
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.
Fig 2 Predicted probabilities of being in each of the five change in substance use categories (change from baseline in average daily amount of main substance)
 Differences in time remaining independent in activities of daily living (ADL) assessed by the modified Rankin scale between patients with pure autonomic.
Catheter Type, Placement, and Insertion Techniques for Preventing Catheter-Related Infections in Maintenance Peritoneal Dialysis Patients: Summary of.
ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;
Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;
Presentation transcript:

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression  Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody  Alzheimer's & Dementia: The Journal of the Alzheimer's Association  Volume 9, Issue 3, Pages 338-345 (May 2013) DOI: 10.1016/j.jalz.2012.01.002 Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 1 Predicted long-term trajectories and effect size estimates: Atri et al study. Mean (A) BDS values and (B) ADL values predicted by longitudinal model for patients in the different medication regimens: combination therapy, ChEI monotherapy, and no therapy. Cohen-defined effect sizes for ADL and BDS values: ChEI monotherapy versus combination therapy, combination therapy versus no therapy, and combination therapy versus ChEI monotherapy. Abbreviations: ADL, Weintraub Activities of Daily Living Scale; BDS, Information-Memory-Concentration subscale of the Blessed Dementia Scale; ChEI, cholinesterase inhibitor; COMBO, combination therapy (ChEI plus memantine); NO-RX, no treatment. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 2 Time to nursing home placement: Lopez et al study. Survival analysis or time to nursing home admission in cohort 1 using the untreated patients as the reference group (A), and time to nursing home admission in cohort 2, using ChEI monotherapy as the reference group (B). Reproduced with permission from Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, DeKosky ST. J Neurol Neurosurg Psychiatry, 2009;80:600–7BMJ Publishing Group Ltd. Abbreviation: ChEI, cholinesterase inhibitor. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 3 Decline rates on neuropsychological tests by persistency group: Rountree et al study. Annualized rates of decline on (A) (E) cognitive, (B) (F) global, and (C) (D) functional measures. The graphs in Figure 3 present the trend of each predicted neuropsychological test value from the adjusted model by the whole drug persistency index group. Each predicted value was regressed on the time since entering the study, taking into consideration unbalanced number of observations. Abbreviations: ADAS, Alzheimer’s Disease Assessment Scale-Cognitive subscale; BPMSE, Baylor Profound Mental State Examination; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PI, Persistency Index (years drug use/years disease); PSMS, Physical Self-Maintenance Scale. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions